Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes Mellitus: the Mass General Brigham Lp(a) Registry.
Lipoprotein(a) 作為糖尿病患者及非糖尿病患者的心血管風險因子:麻省總醫院布萊根醫學中心 Lp(a) 註冊。
Cardiovasc Diabetol 2024-07-25
Role and impact of a specialized cardiometabolic clinic in managing high-risk patients with type 2 diabetes and atherosclerotic cardiovascular disease.
專門心血管代謝診所對於管理高風險2型糖尿病及動脈粥樣硬化心血管疾病患者的角色與影響。
Am J Prev Cardiol 2024-07-29
Assessing Cardiovascular Target Attainment in Type 2 Diabetes Mellitus Patients in Tertiary Diabetes Center in Romania.
在羅馬尼亞三級糖尿病中心評估2型糖尿病患者的心血管目標達成情況。
Pharmaceuticals (Basel) 2024-09-28
Lipid metabolism disorders and albuminuria risk: insights from National Health and Nutrition Examination Survey 2001-2018 and Mendelian randomization analyses.
脂質代謝障礙與白蛋白尿風險:來自2001-2018年國家健康與營養檢查調查及孟德爾隨機化分析的見解。
Ren Fail 2024-11-04
Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.
Adiponectin 可能在 2 型糖尿病患者接受 GLP-1RAs 治療的代謝效應中扮演關鍵角色:一項初步的縱向研究。
Endocrine 2024-11-09
Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus.
2型糖尿病患者中HMGB1依賴的血小板衍生微粒對動脈粥樣硬化風險的影響。
Clin Appl Thromb Hemost 2024-11-26
A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes.
SGLT2 抑制劑對糖尿病患者血漿動脈粥樣硬化生物標記物水平的研究。
J Family Med Prim Care 2024-12-26
Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing.
Lp(a) 能否成為下一個 A1C?數位健康管理工具克服對 Lipoprotein (a) 測試的惰性之案例。
Front Cardiovasc Med 2025-02-25